XML 45 R28.htm IDEA: XBRL DOCUMENT v3.25.4
Net Loss Attributable to Common Stockholders Per Share
 12 Months Ended
Dec. 31, 2025
Earnings Per Share [Abstract]  
Net loss attributable to common stockholders per share Net loss attributable to common stockholders per share
The following table sets forth the computation of the Company’s basic and diluted net loss attributable to common stockholders per share for the years ended December 31, 2025, 2024, and 2023 (in thousands except share and per share data):
 Year Ended December 31,
 202520242023
Numerator
Net loss$(66,539)$(6,020)$(12,148)
Less: net loss allocated to noncontrolling interests— — — 
 
Net loss attributable to common stockholders, basic and diluted$(66,539)$(6,020)$(12,148)
      
Denominator     
Weighted-average common shares outstanding, attributable to common stockholders, basic127,745,939130,611,330135,283,044
Effect of employee stock plans— — — 
Weighted-average common shares outstanding, attributable to common stockholders, diluted127,745,939130,611,330135,283,044
      
Net loss attributable to common stockholders per share, basic$(0.52)$(0.05)$(0.09)
Net loss attributable to common stockholders per share, diluted$(0.52)$(0.05)$(0.09)
Stock-based compensation awards of approximately $11.1 million, $7.2 million, and $9.0 million shares for the years ended December 31, 2025, 2024, and 2023, respectively, were outstanding but were not included in the computation of diluted net income (loss) per share attributable to Cytek Biosciences, Inc. common stockholders, because the effect of including such shares would have been anti-dilutive in the periods presented.